Moderna CEO Stephane Bancel discusses the development of mRNA vaccines, the technology behind them, and the shift in drug development. He shares the moment he realized a Covid-19 vaccine was possible, explains how mRNA works, and the advantages over traditional vaccines. The episode explores the potential of mRNA technology in treating conditions beyond Covid and the risks involved in biotech.

Modern CEO Stephane Bancel discusses company earnings and cost-cutting benefits in response to Covid business decline. Topics include balancing cost efficiency with innovation, progress on a melanoma vaccine, potential accelerated approval, and the impact of AI on drug production and clinical development.

Citi's economist discusses Fed's interest rate decisions. Bank of America predicts a soft landing post high rates. Moderna CEO talks about better-than-expected earnings and RSV vaccine development.

Moderna CEO discusses market share growth, mRNA vaccines, and plans for new RSV vaccine in 2023. Also explores advancements in RSV, flu, and cancer vaccines, potential of single-shot COVID, flu, and RSV combo vaccine, and competition concerns.

Moderna CEO Stephane Bancel discusses joint efforts with Merck to create a skin cancer vaccine. They cover accelerated approval, improved survival rates, expansion into more cancer studies, sales performance, market share, future plans, and the company's impact in saving lives.